tipelukast
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT00295854)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Cysteinyl leukotriene receptorANTAGONIST
Cysteinyl leukotriene receptor antagonist
- Phosphodiesterase 3AINHIBITOR
PDE3A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCc1c(SCCCOc2ccc(C(C)=O)c(OCCCC(=O)O)c2CCC)ccc(C(C)=O)c1O- Mol. weight
- 530.68 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2104988 ↗
Also known as
- 4-(6-acetyl-3-(3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy)-2-propylphenoxy)butyric acid
- kca757
- kca 757
- kca-757
- kca-757
- kca-757
- mn 001
- mn-001
- mn-001
- mn-001
- mn001 cpd
- tipelukast
- tipelukast
- tipelukast
- tipelukast
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05464784 | Phase 2 | Aug 22, 2022 | MediciNova |
| NCT04203901 | Phase 2 | Mar 31, 2020 | CoImmune |
| NCT02503657 | Phase 2 | Mar 1, 2016 | MediciNova |
| NCT02681055 | Phase 2 | Mar 1, 2016 | MediciNova |
| NCT00295854 | Phase 2 | May 1, 2005 | MediciNova |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MediciNova | For profit | 4 | 4 | 1 | 2005 |
| CoImmune | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1